These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22916052)

  • 1. Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly.
    Gravina CF; Bertolami M; Rodrigues GH
    J Geriatr Cardiol; 2012 Jun; 9(2):83-90. PubMed ID: 22916052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering therapy: who can benefit?
    Lewis SJ
    Vasc Health Risk Manag; 2011; 7():525-34. PubMed ID: 21915170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
    Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia: management using optimal lipid-lowering therapy.
    Ito MK
    Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
    Kones R
    Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cardiovascular events in elderly people.
    Andrawes WF; Bussy C; Belmin J
    Drugs Aging; 2005; 22(10):859-76. PubMed ID: 16245959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of lipid disorders in the elderly.
    Playford DA; Watts GF
    Drugs Aging; 1997 Jun; 10(6):444-62. PubMed ID: 9205850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.
    Jacobson TA
    Mayo Clin Proc; 2011 Aug; 86(8):762-80. PubMed ID: 21803958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.